Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 interventional single arm study describing platelet responses and ITP remission rates in adult subjects with immune thrombocytopenia purpura receiving romiplostim

Trial Profile

A phase 2 interventional single arm study describing platelet responses and ITP remission rates in adult subjects with immune thrombocytopenia purpura receiving romiplostim

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 14 Dec 2021 Results of subgroup analysis presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 01 Jun 2020 Results of integrated analysis of five clinical trials evaluating the efficacy and safety of romiplostim self-administration published in the American Journal of Hematology
    • 18 Oct 2019 According to an Amgen media release, based on the results of this trial, the U.S. FDA has approved romiplostim for an additional indication of treatment of newly diagnosed and persistent adult Idiopathic-thrombocytopenic-purpura patients who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top